Skip to main
TVGN

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen is a promising player in the healthcare industry, with a diversified portfolio of biotechnology, AI, and healthcare services. The company's recent focus on developing biotechnology products and AI-based solutions has put them in a position to potentially generate significant revenue through milestone and royalty payments. With their strong focus on innovation and technology, Tevogen is poised for long-term growth and success in the healthcare market.

Bears say

Tevogen is facing several risks that led to a lowering of the stock's price target and a downgrade from Buy to Hold, including dilution risk and a weaker capital markets position due to the announced 50:1 reverse stock split. Additionally, other risk factors such as Clinical/Regulatory Risk, Partnership and Financial Risk, Commercial Risk, Legal and Intellectual Property Risk, and Market Share Risk could further impact the company's financials. The recent decline in share price may also delay the company's commercialization timeline and create pressure on its capital formation and balance sheet flexibility.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.